On March 6, 2023 Therapeutic Solutions International (TSOI) reported plans to initiate ten patient proof-of-concept clinical trial aimed at demonstrating the ability of FloraStilbene to stimulate the immune system in advanced breast cancer patients (Press release, Therapeutics Solutions International, MAR 6, 2023, View Source [SID1234628228]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"Therapeutic Solutions International has been working on, and filing patents, in the area of cancer immunotherapy with internationally renowned opinion leaders such as Dr. Santosh Kesari since 2015"
Tweet this
The Company has previously been granted a patent on utilization of pterostilbene and pterostilbene compositions for synergy with cancer immunotherapy such as interleukin-21, as well as suppression of cancer derived immune inhibitory agent enzymes such as indolamine 2,3 dioxygenase2. By combining previous experiences with immune modulation, the Company announced the creation of a novel immune stimulatory adjuvant combining pterostilbene with RU-486, termed "FloraStilbene". Preclinical data, for which intellectual property has been filed, demonstrated FloraStilbene overcame immune suppression induced in the 4T1 mouse model of triple negative breast cancer.
"FloraStilbene represents a non-toxic approach to overcoming breast cancer induced immune suppression, which acts as a significant barrier to efficacy of oncology immunotherapy," said Dr. James Veltmeyer, Chief Medical Officer of the Company. "I am eager to lead this clinical trial, which if successful, will serve as the basis for a new approach to increase efficacy of drugs such as Herceptin and checkpoint inhibitors."
"Therapeutic Solutions International has been working on, and filing patents, in the area of cancer immunotherapy with internationally renowned opinion leaders such as Dr. Santosh Kesari since 2015," said Famela Ramos, President and Chief Executive Officer of Res Nova Bio. "We are excited to leverage these deep and broad resources to rapidly enter the clinic to address such a major unmet medical need."
"One of the guiding principles of our Company has been to bring hope to patients for which limited options exist," said Timothy Dixon, President, and Chief Executive Officer of Therapeutic Solutions International. "We strongly believe that immuno-adjuvant approaches such as FloraStilbene will greatly increase the potency of numerous existing therapies, as well as reducing various toxicities."